001     1052301
005     20260122203309.0
024 7 _ |a 10.1111/joor.70039
|2 doi
024 7 _ |a 0305-182X
|2 ISSN
024 7 _ |a 1365-2842
|2 ISSN
024 7 _ |a 10.34734/FZJ-2026-00916
|2 datacite_doi
037 _ _ |a FZJ-2026-00916
082 _ _ |a 610
100 1 _ |a Prott, Lea S.
|0 0000-0003-0792-0830
|b 0
|e Corresponding author
245 _ _ |a Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Myoarthropathic Symptoms Associated With Temporomandibular Disorders—A Pilot Randomised Controlled Trial
260 _ _ |a Oxford [u.a.]
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1769095107_2047
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a ABSTRACTBackground: Transcutaneous auricular vagus nerve stimulation (taVNS) is a safe and feasible treatment for a variety of acuteand chronic pain conditions. However, no evidence about taVNS effectiveness in patients with chronic pain associated with tem-poromandibular disorders (TMD) is available.Objective: To evaluate the feasibility of and compliance with taVNS in participants experiencing chronic TMD pain and poten-tial effects on pain, psychological well-being, muscle activity, and kinematics.Methods: Twenty adults with chronic TMD pain were randomised to receive taVNS (n = 10) or sham (n = 10). In the taVNSgroup, stimulation was performed on the left tragus for 4 h daily (25 Hz, pulse width 250 μs, 28 s on/32 s off). In the sham group,an inactive non-functional sham electrode was used. Patient-reported outcome measures (GCPS, PHQ-9, GAD-7, PHQ-15, andOHIP- G14), muscle activity, and kinematics were assessed at baseline, 4 weeks, and 8 weeks. Compliance was assessed using asmartphone app, which recorded daily stimulation time and intensity.Results: Recruitment and retention rates were high (100% and 90%, respectively), with 83% adherence to the intervention.Participants receiving taVNS showed a large effect on oral health-related quality of life, and at least a small but potentially impor-tant effect on pain intensity, anxiety, depression, severity of somatic symptoms, muscle activity, and kinematics. However, noneof these differences were statistically significant. No serious adverse events were identified.
536 _ _ |a 5251 - Multilevel Brain Organization and Variability (POF4-525)
|0 G:(DE-HGF)POF4-5251
|c POF4-525
|f POF IV
|x 0
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Kaldenhoven, Vanessa
|b 1
700 1 _ |a Hugger, Alfons
|b 2
700 1 _ |a Langner, Robert
|0 P:(DE-Juel1)131693
|b 3
|u fzj
700 1 _ |a Gierthmuehlen, Petra C.
|b 4
700 1 _ |a Gierthmuehlen, Mortimer
|b 5
773 _ _ |a 10.1111/joor.70039
|g Vol. 52, no. 12, p. 2351 - 2360
|0 PERI:(DE-600)2007587-X
|n 12
|p 2351 - 2360
|t Journal of oral rehabilitation
|v 52
|y 2025
|x 0305-182X
856 4 _ |u https://juser.fz-juelich.de/record/1052301/files/J%20of%20Oral%20Rehabilitation%20-%202025%20-%20Prott%20-%20Transcutaneous%20Auricular%20Vagus%20Nerve%20Stimulation%20for%20the%20Treatment%20of.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:1052301
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131693
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5251
|x 0
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 1
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-06
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ORAL REHABIL : 2022
|d 2025-01-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-7-20090406
|k INM-7
|l Gehirn & Verhalten
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-7-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21